Related Experiment Videos

Activation of FGF receptors by mutations in the transmembrane domain

Y Li1, K Mangasarian, A Mansukhani

  • 1Department of Microbiology and Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016, USA.

Oncogene
|March 27, 1997
PubMed

Insights

Mutations in fibroblast growth factor receptors (FGFRs) cause skeletal disorders. The achondroplasia mutation in FGFR-3 leads to constitutive receptor activation, disrupting normal bone growth regulation.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cell Signaling

Background:

  • Fibroblast growth factor receptors (FGFRs) are membrane-spanning tyrosine kinases crucial for cell proliferation, differentiation, and development.
  • Mutations in FGFRs are linked to dominant human skeletal disorders.
  • The specific mutation (Gly 380-->Arg) in FGFR-3 causing achondroplasia (ACH) was investigated for its functional consequence: loss of function or constitutive activation.

Purpose of the Study:

  • To investigate the effect of mutations in the transmembrane regions of murine FGFR-2 and FGFR-3 on receptor activity.
  • To determine if the achondroplasia mutation in FGFR-3 and similar mutations in FGFR-2 lead to constitutive receptor activation.

Main Methods:

  • Site-directed mutagenesis was performed on the transmembrane regions of murine FGFR-2 and FGFR-3.
  • Receptor activity was assessed by measuring autophosphorylation in L6 cells without ligand.
  • Transforming activity was evaluated in NIH3T3 fibroblasts.
  • Inhibition of myogenic differentiation in the absence of growth factor was assessed.

Main Results:

  • The achondroplasia mutation in FGFR-3 and two analogous mutations in FGFR-2 resulted in constitutive receptor activation.
  • Activated receptors showed ligand-independent autophosphorylation, transforming activity in NIH3T3 cells, and inhibition of myogenic differentiation.
  • The transmembrane regions of FGFR-2 and FGFR-3 play a regulatory role in receptor function.

Conclusions:

  • The achondroplasia mutation in FGFR-3 creates a constitutively active, dominant oversignaling receptor independent of FGF binding.
  • These findings support a role for FGF signaling as a negative regulator of bone growth.
  • Dysregulation of FGFR signaling through transmembrane mutations contributes to skeletal disorders.

Related Concept Videos